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Background. Head and neck soft tissue sarcomas (HNSTS) constitute a rare and heterogeneous cancer entity. Management
remains a challenge due to the rarity and varied biological behaviour among various subtypes.,is systematic review examines the
characteristics of tumours and patients with HNSTS. Materials and Methods. A systematic literature review and meta-analysis
were performed using the electronic databases PubMed and Embase. Eight eligible studies were identified, and 13 variables were
extracted from each study including 5-year overall survival (OS) rate and 5-year disease-free survival (DFS) rate. Results. We
identified eight studies (n� 1,120 patients; 739 males (66%)) from six different countries). In total, 24 histological subtypes were
found, and 20% of the sarcomas (n� 215) could not be subclassified. 607 sarcomas (57%) were <5 cm in diameter, and 945
sarcomas (84%) were grade 3. 1,059 patients (90%) underwent surgery. Estimated 5-year OS was 74% (95% CI; 0.63–0.84%) and 5-
year DFS was 56% (95% CI; 38–74%). Conclusion. HNSTS holds a relative poor prognosis possibly explained by the heterogeneity
of the disease. Treatment of HNSTS has shown to be highly diverse, underlining the importance of uniformed treatment guidelines
in order to achieve improved survival outcomes.
1. Introduction
Head and neck soft tissue sarcomas (HNSTS) are a rare
and heterogeneous group of malignancies accounting for
approximately 1% of all head and neck malignancies.
HNSTS represents 10% of all soft tissue sarcomas [1].
More than 80 histological subtypes are distinguished in
the 2013WHO classification [2]. Because of this rarity and
the diverse clinical behaviours, management of HNSTS
can be challenging and should be carried out in a mul-
tidisciplinary centre with expertise and experience in
sarcomas [3].
Surgery remains to be the primary treatment choice,
even though it is difficult to achieve free surgical margins due
to the anatomy of the head and neck region [4]. When
combined with surgery, radiotherapy may improve overall
prognosis for some HNSTS depending on the histological
type, whereas a better outcome is achieved for some his-
tological subtypes when surgery is combined with chemo-
therapy, e.g., angiosarcoma, rhabdomyosarcoma, and
synovial sarcoma [3, 5, 6].
,e purpose of this study was to systematically review
the literature on adult patients diagnosed with HNSTS and
report the distribution of histological subtypes, treatment,
and overall survival (OS) rates.
2. Materials and Methods
2.1. Search Strategy and Eligibility Criteria. ,e electronic
databases PubMed and Embase were used for searching.
,e search strategy in PubMed included the following
keywords: “Head and Neck,” “Oral Cavity,” “Pharynx,” and
Hindawi
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2 Sarcoma
“Sarcoma.” e search strategy in Embase included the
keywords “Head and Neck Sarcomas.” Studies published
from 2000 until March 2018 reporting patient databases of
soft tissue sarcomas in the head and neck region with a
minimum of 20 patients (>18 years of age at diagnosis)
were included. Studies reporting both localized disease and
metastatic disease were included. Exclusion criteria were
radiation-induced sarcomas, bone sarcomas, and studies
that solely reported specic histological subtypes. Due to an
update in WHO classication of soft tissue tumours in
1994, studies reporting patient cases from before 1994 were
excluded.
2.2. Data Extraction. We extracted data on country, number
of cases, period, gender, age, histological subtypes, tumour
size, and grading according to the French Federation of Cancer
Centres Sarcoma Group (grade I, grade II, grade III, and
unknown). Furthermore, T stage (0, 1, 2, 3, and 4), treatment
(surgery, radiotherapy, and/or chemotherapy), surgical mar-
gins (R0, R1, R2, and unspecied/unknown), median follow
up, 5-year OS, and 5-year disease-free survival (DFS) were also
extracted. We applied the model of random eects to perform
a meta-analysis of 5-year OS and 5-year DFS. Data analysis
was performed in Stata, and a p value< 0.05 was considered
statistically signicant.
3. Results
We identied 2,056 publications, of which eight studies
(1,120 cases; 66% males) from six dierent countries met the
inclusion criteria. All studies reported the median age, which
ranged from 35 to 68.5 years. In four studies (n 897), 73%
of the patients were more than 50 years of age (Table 1 and
Figure 1).
Sarcomas with unidentied histology (n 215) and
uncommon sarcoma subtypes (n 141) constituted one-
third of the cohort (n 1,083) being the most frequent
histological subtypes.ese were followed by brosarcomas/
bromatous sarcomas (n 136), vascular sarcomas
(n 125), and leiomyosarcomas (n 89). Noteworthy, in
some of the included studies, the group “uncommon sar-
comas” consisted of several sarcoma subtypes traditionally
perceived as common sarcomas (e.g., rhabdomyosarcomas)
(Table 2 and Figure 2). is was mainly seen in studies
including a small number of cases. Hence, several of the
cases classied as “uncommon sarcomas” could potentially
be reclassied within one of the specied subtypes.
In seven studies (n 1,090), the median follow-up period
ranged from 23.8 to 72months. Five-year OS was reported in
ve studies, 5-year DFS was reported in three studies, and
their values were 74% (95% CI; 0.63–0.84%) and 56 % (95%
CI; 38–74%), respectively (Table 1 and Figures 3 and 4).
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Figure 1: PRISMA 2009 ¡ow diagram.
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Six studies (n� 1,060) reported tumour size as a binary
outcome (<5 cm or >5 cm), two studies reported median
tumour size, and one study reported both mean tumour size
and tumour size as a binary outcome. In 57% of the cases, the
tumour diameter was <5 cm in diameter at the time of
diagnosis. Mean tumour size ranged from 2.7 to 4.8 cm
(n� 55). Tumour grading was stated in all studies included
(n� 1,120). 84% of the tumours were grade III, 7% were
grade II, 5% were grade I, and 3% were unspecified or
unknown grade. ,e surgical resection margins were stated
in seven studies (n� 1,092). 60% of the tumours had clear
surgical margins (R0), 13% had microscopic involved
margins (R1), 18% had macroscopic involved margins (R2),
and 1% had unknown margins (Table 1).
All studies (n� 1,120) reported treatment strategy
(Table 3).
4. Discussion
To our knowledge, this is the first systematic review and
meta-analysis to explore patient and tumour characteristics
including OS, DFS, and treatment strategies for patients with
Table 2: Histological subtypes.
Mahmoud
et al. [7]
Andra¨
et al. [8]
Gonza´lez-
Gonza´lez et al.
[9]∗ Vitzthumet al. [10]∗ Tejaniet al.[6]
Penel
et al.
[11]∗
Sidappa and
Krishnamurthy
[12]
Park
et al.
[13]
Total
Alveolar soft part
sarcoma — — — — 1 — — 3 4
Angiosarcoma — 9 — 14 4 5 — 15 47
Carcinosarcoma — — — — 1 — — — 1
Chondrosarcoma — — — — — — — 8 8
DFSP▪ — — — 1 — — 16 17
Epithelioid sarcoma — — — — 1 1 — — 2
Ewing’s sarcoma/
PNET◊ — — — — — — — 4 4
Fibrosarcoma/
fibromatous
sarcoma○ 125 — — — 1 2 1 7 136
Histiocytic sarcoma — — — — 1 — — — 1
Leiomyosarcoma 76 — — 5 3 — 1 4 89
Lipomatous
sarcoma∆ 31 — — 3 4 — — 10 48
Low-grade
fibromyxoid sarcoma — — — — — — — 2 2
MFH/undiff. pleo./
UPS∞ — 5 — 9 — 2 6 3 25
Neurofibromatous
sarcoma□ 46 — 9 1 — — 5 — 61
Osteosarcoma — — — — — — — 5 5
Others• — 8 — 3 — — — 5 16
Peripheral
neuroectodermic
tumour
— — — — — 3 — — 3
Rhabdomyosarcoma — — 7 1 5 7 — 24 44
Spindle cell — — — 4 3 — 10 9 26
Synovial sarcoma 34 4 — 6 6 2 1 7 60
Uncommon sarcoma
subtypes† 139 — — — — — 2 — 141
Undifferentiated
sarcoma — — — — — 3 — — 3
Unidentified
sarcoma◆ 215 — — — — — — — 215
Vascular sarcoma‡ 122 — — 2 — — 1 — 125∗Not all of the histological subtypes were reported. ▪Dermatofibrosarcoma protuberans. ◊Primitive neuroectodermal tumour. ○Including fibrosarcoma
NOS, fibromyxoma, and fibrous histiocytoma. ∆Including myxosarcoma, angiomyxoma, atypical lipoma, liposarcoma NOS, fibromyxolipoma, myxoid,
round cell, pleomorphic, mixed, and dedifferentiated liposarcoma, and spindle cell lipoma. ∞MFH �malignant fibrous histiocytoma, undiff.
pleo. � undifferentiated pleomorphic sarcoma. UPS � unclassified pleomorphic sarcoma. □Including neurosarcoma and malignant peripheral nerve
sheath tumour. •Andra¨ et al. [8], not otherwise specified; Vitzthum et al. [10], dendritic cell sarcoma, chordoma, and hemangioengothelioma; Park et al.
[13], folicular dendritic cell sarcoma and teratocarcinosarcoma. †Including clear cell, dermatofibrosarcoma, rhabdomyosarcoma, epithelioid, desmo-
plastic small round cell tumour, fascial, infantile, angiomatoid, fibrous histiocytoma, rhabdoid, giant cell tumour of soft part, and alveolar soft part.◆Sarcomatosis not otherwise specified (NOS), spindle cell, giant cell, small cell, and undifferentiated sarcoma. ‡Including hemangiosarcoma, malignant
hemangioendothelioma, epithelioid hemangioendothelioma, malignant hemangiopericytoma, hemangiopericytoma, and lymphangiosarcoma.
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a HNSTS. In the meta-analysis, the pooled results showed a
5-year OS of approximately 75% and a 5-year DFS of nearly
50%.
Surgery remains the cornerstone of treatment of HNSTS,
but the close relation to vital anatomic structures compli-
cates this treatment strategy, explaining the relatively low 5-
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Figure 2: Histological subtypes.
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Figure 3: 5-year overall survival.
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Figure 4: 5-year disease-free survival.
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6 Sarcoma
year DFS. Several factors influence the degree of surgical
resection, e.g., tumour location and size, the extend of in-
vasion, and the performance status of the patient [14]. Even
though surgery with wide resection margins remains a
difficult task, this review shows that 90% of the patients were
treated with surgery (± radiation therapy and/or chemo-
therapy), and wide surgical margins were obtained in 60% of
the cases.
In the present study, 53% of the patients were treated
with radiation therapy with or without surgery. Studies in
patients with truncal or extremity soft tissue sarcomas have
demonstrated an improved local control following adjuvant
radiation therapy in patients with large grade II and grade III
sarcomas. Furthermore, retrospective studies have shown an
approximately 10% improvement in OS following adjuvant
radiation therapy in patients with grade III sarcomas [15].
Similarly, radiation therapy has also been found to improve
OS in HNSTS [7].
In order to improve 5-year DFS and 5-year OS, the value
of neoadjuvant chemotherapy in high-graded truncal or
extremity soft tissue sarcomas has been investigated.
However, the study was closed prematurely because supe-
riority for neoadjuvant treatment was not to be expected
[16]. Nevertheless, neoadjuvant chemotherapy still holds a
potential improvement in the prognosis of HNSTS, and
prospective, multicentre studies are needed in order to gain
information about the effect of neoadjuvant treatment in-
cluding chemotherapy and radiation therapy. Furthermore,
in a study by Blay et al., early evaluation by a multidisci-
plinary team demonstrated a significant improvement in
relapse-free survival [17]. Hence, HNSTS should only be
managed by a specialist multidisciplinary environment in
order to ensure a uniform treatment protocol [18].
More than 80 histological subtypes of HNSTS have been
identified [2]. In order to predict risk of metastasis and
relapse, it is important to identify the exact histological
classification. In this systematic review, 215 sarcomas could
not be classified, and additional 141 sarcomas were classified
as “uncommon sarcomas.” It is remarkable that one-third of
the cohort constituted of sarcomas with unknown histology
and uncommon sarcoma subtypes. Noteworthy, the clas-
sification of soft tissue sarcomas has evolved considerably
during the past decades, especially due to evolvement in
immunohistochemical and genetic/molecular methods [19].
It is likely that a large number of the cases included in the
present review would be reclassified if classified today.
Furthermore, many of the cases where a specific pathological
classification could not be obtained could probably be
classified using modern methods. ,is may complicate
applying the results of the present review on newly di-
agnosed patients with HNSTS. A high expertise in histo-
logical classification is crucial if more knowledge about
behaviour and treatment of sarcomas must be achieved. It
emphasizes the need of histological reevaluation of a special
trained pathologist in the highest national level before
treating and before publishing data of sarcomas.
,e present systematic review and meta-analysis hold
important limitations. Inclusion and exclusion criteria as
well as staging and treatment varied between the included
studies, which complicates interpretation. ,e included
studies reported a few cases of sarcomas, which were not
classified as soft tissue sarcomas; however, these constituted
only a small part (1.3%) of the total cases included. ,e
included studies originated from six countries, and the
majority of the cases were obtained from a single study. All
studies were retrospective, and the cases were obtained
during long follow-up periods.
5. Conclusions
HNSTS is a rare and heterogeneous tumour group with great
differences in OS and DFS. ,e pooled results showed a 5-
year OS of approximately 75% and a 5-year DFS of nearly
50%. However, studies show varying prognoses demon-
strating the difficulty in treating HNSTS underlining the
importance of uniformed treatment guidelines in order to
achieve improved survival outcomes.
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